Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

22
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
22

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Leukemia·2026
Same author

Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients.

International journal of molecular sciences·2026
Same author

Identification of a Novel, Oncogenic and Targetable <i>TPR::ABL2</i> Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

EJHaem·2026
Same author

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

Stem cell reports·2026
Same author

Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?

Blood neoplasia·2025

Video Experimental Relacionado

Updated: Feb 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

El primer inhibidor de la quinasa aprobado para la LMA

John E J Rasko1, Timothy P Hughes2

  • 1Centenary Institute, University of Sydney and Cell & Molecular Therapies at Royal Prince Alfred Hospital, Australia.

Cell
|November 18, 2017
PubMed
Resumen

Las mutaciones activadoras en FLT3 son comunes en la leucemia mieloide aguda (LMA) y están relacionadas con resultados deficientes. La midostaurina, un inhibidor de la multicinasa, es una nueva opción de tratamiento para la LMA con mutación FLT3.

Más Videos Relacionados

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

980
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

829

Videos de Experimentos Relacionados

Last Updated: Feb 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

980
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

829

Área de la Ciencia:

  • Hematología
  • En el campo de la oncología
  • Farmacología

Sus antecedentes:

  • Las mutaciones activadoras de la tirosina quinasa 3 tipo FMS (FLT3) se encuentran en aproximadamente el 30% de los casos de leucemia mieloide aguda (LMA).
  • Estas mutaciones FLT3 están asociadas con un mayor riesgo de recaída y un peor pronóstico en pacientes con LMA.

Objetivo del estudio:

  • Para resaltar la importancia de las mutaciones FLT3 en la LMA.
  • Introducir la midostaurina como un nuevo agente terapéutico para la LMA con mutación FLT3.

Principales métodos:

  • Revisión de los datos clínicos y de las aprobaciones terapéuticas.
  • Discusión del mecanismo de la midostaurina como inhibidor de la multicinasa.

Principales resultados:

  • La midostaurina representa el primer medicamento aprobado para la LMA desde el año 2000.
  • La midostaurina es el primer inhibidor de la multicinasa aprobado específicamente para el subtipo FLT3 mutante de la LMA.

Conclusiones:

  • La midostaurina ofrece un enfoque de tratamiento dirigido para un subconjunto significativo de pacientes con LMA.
  • La aprobación de Midostaurin marca un avance significativo en el tratamiento de la LMA.